ANTIBODY CAPABLE OF BINDING TO NOVEL CORONAVIRUS (SARS-COV-2) AND SARS CORONAVIRUS (SARS-COV)

WIPO Patent Application WO/2023/002944

A1

[Problem] The present invention addresses the problem of providing a novel antibody that can prevent and/or treat SARS or COVID-19 infection.　Provided is an antibody which comprises heavy-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:1, heavy-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:2, heavy-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:3, light-chain CDR1 comprising the amino acid sequence represented by SEQ ID NO:4, light-chain CDR2 comprising the amino acid sequence represented by SEQ ID NO:5, and light-chain CDR3 comprising the amino acid sequence represented by SEQ ID NO:6 and which is capable of binding to a receptor binding domain (RBD) of S1 subunit of SARS-CoV or SARS-CoV-2, or an antibody fragment of the antibody.

JP2023521361	Aptamers for use in treating coronavirus infections
WO/2022/026592	ANTIBODY MOLECULES TO CORONAVIRUS AND USES THEREOF
WO/2022/079359	SARS-COV-2 CORONAVIRUS-NEUTRALIZING ANTIBODY

WATANABE SHINYA (JP)
IMAI JUNICHI (JP)
SHIGA HATSUKI (JP)
SATO SHIGEKO (JP)
MATSUKURA SUSUMU (JP)
HOSHI HIROTAKA (JP)

PCT/JP2022/027860

January 26, 2023

July 15, 2022

Click for automatic bibliography generation  

PUBLIC UNIV CORPORATION FUKUSHIMA MEDICAL UNIV (JP)
MEDICROME INC (JP)
FUKUSHIMA CELL FACTORY INC (JP)

C07K16/10; A23L33/18; A41D13/11; A61K8/64; A61K9/12; A61K39/395; A61K49/00; A61P31/14; A62B18/02; C07K16/46; C07K17/00; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/13; C12N15/63; C12P21/08

WO2021045836A1

2021-03-11

KR102229225B1	2021-03-19
KR102205028B1	2021-01-20
CN111592594A	2020-08-28

MUTSUKI PARTNERS (JP)

View/Download PDF      PDF Help

Previous Patent: BIOMARKER FOR PREDICTING PROGNOSIS OF CANCER PATIENT, METHOD FOR PREDICTING PROGNOSIS OF CANCER PATI...

Next Patent: COVER DEVICE AND IMAGING DEVICE